Medicine
from24/7 Wall St.
17 hours ago50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today
Xenon Pharmaceuticals and Relmada Therapeutics surged on positive clinical trial data, with Xenon's epilepsy drug azetukalner achieving a 53.2% seizure reduction and Relmada advancing its bladder cancer treatment NDV-01.